GlassScriptPhysician profile
Melanie L Jackson
NPI 1598797417
$4,148.84
in general payments reported to CMS, 2019-2025
36 companies · $1,229 in 2025
The $1,229 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $702 · 2020: $365 · 2021: $841 · 2022: $207 · 2023: $234 · 2024: $571 · 2025: $1,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,025 · Education: $9.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,024.87 |
| Education | $9.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,328.28 | 2019-2025 | |
| Janssen Biotech, INC. | $438.22 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $437.67 | 2019-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $213.81 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $211.03 | 2019-2025 | |
| Qol Medical, LLC | $193.45 | 2024-2025 | Sucraid, Sucraid |
| Ipsen Biopharmaceuticals, INC | $179.07 | 2024-2025 | Iqirvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.24 | 2019-2021 | |
| Echosens North America, INC. | $115.85 | 2019 | |
| Medtronic, INC. | $84.53 | 2024 | Interstim |
| Biofire Diagnostics, LLC | $68.05 | 2019 | |
| Intercept Pharmaceuticals, INC. | $67.60 | 2020-2025 | |
| Celgene Corporation | $60.32 | 2021-2024 | Zeposia |
| Endo Pharmaceuticals INC. | $54.34 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $51.67 | 2024-2025 | Dupixent |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $48.38 | 2019-2025 | |
| Braintree Laboratories, INC. | $36.85 | 2019-2021 | |
| Allergan, INC. | $34.81 | 2019 | |
| Aimmune Therapeutics, INC. | $34.49 | 2023 | |
| Novo Nordisk INC | $33.77 | 2024-2025 | Tresiba, Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $32.07 | 2025 | Voquezna |
| Genzyme Corporation | $25.67 | 2025 | |
| Alfasigma USA, INC. | $24.43 | 2020 | |
| Biocon Biologics INC | $22.76 | 2025 | Yesintek |
| Lilly USA, LLC | $21.79 | 2025 | Omvoh |
| Mallinckrodt Hospital Products INC. | $20.03 | 2020 | |
| Fresenius Kabi USA, LLC | $18.16 | 2023 | Idacio |
| Stryker Corporation | $17.63 | 2025 | Neptune |
| Ardelyx, INC. | $16.53 | 2023 | Ibsrela |
| Merck Sharp & Dohme LLC | $15.54 | 2023 | Dificid |
| Ucb, INC. | $15.43 | 2019 | |
| Boston Scientific Corporation | $13.62 | 2023 | Captivator II |
| Ferring Pharmaceuticals INC. | $12.92 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.12 | 2020 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 | |
| Intra-Sana Laboratories | $7.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.